From our September 2020 Newsletter

CHMP Grants Positive Opinion for Expanded Use of Otsuka’s Deltyba® (delamanid) in Children and Adolescents Weighing at Least 30kg Treated for Pulmonary Multi-drug Resistant Tuberculosis

The European Medicines Agency has updated its stance on Deltyba—with implications for children with DR-TB.

Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson

The driving contributor to safer, all-oral TB regimens may not be who you think, with more credit due to the government than private enterprises.

From our August 2020 Newsletter

Union welcomes EC authorization of TB Alliance’s BPaL treatment for drug-resistant TB
On August 3rd, a new treatment developed by the TB Alliance has been approved by the European Commission for some of the most drug-resistant forms of TB. Learn more about the new Pretomanid drug here.

From our July 2020 Newsletter

COVID-19 Disruptions May Raise Cancer, HIV, TB Cases, Deaths Globally
Mounting evidence suggests the ongoing pandemic will have significant implications for the treatment and pathology of other burdensome diseases—tuberculosis included.

Rapid Drug-Resistant Tuberculosis Diagnostics Test is Launched
The new Xpert MTB/XDR from Cepheid offers huge advancements in the profiling of MDR and XDR-TB—minimizing turnaround time and complexity while increasing accessibility.

From our June 2020 Newsletter

FDA Approves Pediatric Formulation of Bedaquiline for Multidrug-Resistant TB
Bedaquiline first received approval from the FDA in 2012 for use in adult patients. Now, the FDA has given Johnson & Johnson accelerated approval to use the drug on pediatric patients five years and older. You can access the FDA’s updated label for the drug here.

Tuberculosis in Children: Underdiagnosed and Undertreated
A deeper dive into comprehensive, up-to-date information on treating tuberculosis in children.

TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for Pretomanid as part of New Regimen
Mylan’s new Named Patient Access Program has been designed to make pretomanid accessible in countries previously lacking access to the drug.

From our May 2020 Newsletter

Hope of a cure for individuals with XDR-TB.

WHO launches online course to improve diagnosis of drug-resistant TB

WHO/Europe has launched a new online course to strengthen the capacity to diagnose drug-resistant tuberculosis (DR-TB) using molecular techniques. This free course, entitled “Drug-resistant tuberculosis: how to interpret rapid molecular test results”, is available on the OpenWHO platform and includes opportunities for participants throughout the world to seek expert advice for their diagnostic questions.

Korea upgrades guidelines for multidrug-resistant TB
Korean patients with multidrug-resistant tuberculosis (TB) will likely get faster and better treatment than now.

From our April 2020 Newsletter

EMA panel backs pretomanid for drug-resistant TB
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of pretomanid FGK (FGK Representative Service GmbH) for drug-resistant tuberculosis (TB).

From our March 2020 Newsletter

On March 26, 2020, RESIST-TB hosted a webinar featuring Dr. Dan Everitt to discuss the recently published work on the NiX-TB trial, which focuses on treatment of extensively drug-resistant tuberculosis (XDR-TB). To read the publication, the article can be found below (publication #2). The presentation slides and recording have been posted here.

From our February 2020 Newsletter

No news.

From our January 2020 Newsletter

Submit Feedback To Inform Overhaul of
In February,—the world’s largest public repository of clinical research registry and results database—will celebrate its 20th anniversary. Over the next few months, the National Library of Medicine (NLM) will be Engaging Users To Support the Modernization of


WHO announces updates on new molecular assays for the diagnosis of tuberculosis and drug resistance
Significant improvements to the diagnosis of tuberculosis (TB) and rifampicin resistance in adults and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO). It's easy.

From Our December 2019 Newsletter

WHO announces changes to the treatment of drug-resistant tuberculosis
Significant improvements in treatment outcomes and quality of life for patients with drug-resistant tuberculosis (TB) are expected, following key updates to treatment approaches, announced by WHO.

TB Alliance responds to questions raised by activists in relation to pretomanid
MSF, TAG and TB CAB raised a number of outstanding medical and research questions regarding pretomanid and the regimen BPaL.

From our November 2019 Newsletter

ATS, CDC, ERS and IDSA publish new clinical guideline for the treatment and prevention of drug-resistant TB

New guideline emphasizes treatment of drug-resistant TB with all-oral regimens and provides recommendations for treatment of all contacts to multidrug-resistant TB patients.


This article reports the 2018 survey results regarding the assessment of access to treatment strategies for tuberculosis conducted by the International Union Against Tuberculosis and Lung Disease (The Union) drug-resistant TB Working Group in collaboration with RESIST-TB. Read the full article here.

From our October 2019 Newsletter

The WHO Global Tuberculosis Report 2019 is Out

The WHO 2019 Global Tuberculosis Report has recently been published. It was found that the global MDR-TB epidemic increased by approximately half a million new cases of rifampin-resistant TB (of which 78% had multidrug-resistant TB) in 2018. Check out the link to the full global TB report 2019 below, and other recent news in DR-TB.

From our September 2019 Newsletter

Palliative care and symptom relief for people affected by multi-drug resistant tuberculosis 
Below is the most recent State of the Art article from IJTLD, which discusses the use of palliative care and symptom relief (PCSR) for people affected by MDR-TB.